Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition

It is estimated that ~50% of patients with melanoma harbour B-Raf (BRAF)V600 driver mutations, with the most common of these being BRAFV600E, which leads to the activation of mitogen-activated protein kinase proliferative and survival pathways. BRAF inhibitors are used extensively to treat BRAF-muta...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Int J Oncol
Hoofdauteurs: Rowdo, Florencia Paula Madorsky, Barón, Antonela, Gallagher, Stuart John, Hersey, Peter, Emran, Abdullah Al, Von Euw, Erika M., Barrio, María Marcela, Mordoh, José
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: D.A. Spandidos 2020
Onderwerpen:
Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170042/
https://ncbi.nlm.nih.gov/pubmed/32236593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2020.5031
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items